PharmaCyte Biotech Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About PMCB
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Find out what a historical investment in PharmaCyte Biotech Inc would be worth today using our PMCB stock calculator.
$6.93M
-
0.00%
700.64K
$1.02
$0.94
$1.00
$1.90
$0.63
Ready to start your investing journey with Stake?
Open an accountPMCB FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in PMCB
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in PMCB
on Stake
Buy PMCB from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of PMCB from only US$10 with fractional shares
